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Endpoint: To assess early urinary (GU) and rectal (GI) toxicities after helical tomotherapy
Stereotactic body radiation therapy (SBRT), and to determine their predictive factors.
Methods: Since May 2012, 45 prostate cancer patients were treated with eight frac-
tions of 5.48 (low risk, 29%) or 5.65 Gy (intermediate-high risk, 71%) on alternative days
over 2.5 weeks. The exclusion criteria were Gleason score 9–10, PSA >40 ng/mL, cT3b-4,
IPSS ≥20, and history of acute urinary retention. During the follow-up, a set of potential
prognostic factors was correlated with urinary or rectal toxicity.
Results: The median follow-up was 13.8 months (2–25 months). There were no grade ≥3
toxicities. Acute grade 2 GU complications were found in a 22.7% of men, but in 2.3%
of patients at 1 month, 0% at 6 months, and 0% at 12 months. The correspondent figures
for grade 2 GI toxicities were 20.4% (acute), 2.3% (1 month), 3.6% (6 months), and 5%
(12 months). Acute GI toxicity was significantly correlated with the rectal volume (>15 cm3)
receiving 28 Gy, only when expressed as absolute volume. The age (>72 years old) was
a predictor of GI toxicity after 1 month of treatment. No correlation was found, however,
between urinary toxicity and the other analyzed variables. IPSS increased significantly at the
time of the last fraction and within the first month, returning to the baseline at sixth month.
Urinary-related quality of life (IPSS question 8 score), it was not significantly worsen dur-
ing radiotherapy returning to the baseline levels 1 month after the treatment. At 12 months
follow-up patient’s perception of their urinary function improved significantly in comparison
with the baseline.
Conclusion: Our scheme of eight fractions on alternative days delivered using helical
tomotherapy is well tolerated. We recommend using actual volume instead of percentual
volume in the treatment planning, and not to exceed 15 cm3 of rectal volume receiving
25 Gy in order to diminish acute GI toxicity.≥
Keywords: prostate cancer, stereotactic body radiation therapy, tomotherapy, predictors toxicity, common toxicity
criteria, IPSS
INTRODUCTION
The Canadian Association of Radiation Oncology defines stereo-
tactic body radiation therapy (SBRT) as the precise delivery of
highly conformal and image-guided hypofractionated external-
beam radiotherapy, delivered in a single or few fraction(s) to an
extracraneal body target with doses at least biologically equivalent
to a radical course when given over a protracted convention-
ally (1.8–3.0 Gy/fraction) fractionated schedule (1). The American
Society for Radiation Oncology has recently stated that “data sup-
porting the use of SBRT for prostate cancer have matured to a
point where SBRT could be considered an appropriate alterna-
tive for selective patients with low to intermediate-risk disease.”
There are not yet available data from controlled randomized trials
comparing SBRT with moderate hypofractionated or normofrac-
tionated radiation therapy. Most of the SBRT studies are phase
II prospective trials using a dedicated robotic linear accelerator
(Cyberknife, Accuracy, Sunnyvale, CA, USA) (2–11). The most
common prescriptive dose is five fractions of 7–7.5 Gy (12). Given
the prostate cancer radiobiology, tumor cells receive biologically
equivalent doses as high as 85–91 Gy (α/β 1.5), which ensures a
biochemical recurrence free survival over 90% at 3–5 years for low
and intermediate risk. Acute and late grade ≥3 events are rare in
these selected studies. Recently, a few phase II trials on prostate
SBRT using non-robotic linear accelerators have been published
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with limited numbers of patients and short follow up. There is
a limited experience on this approach (13–17). The theoretical
advantages are that the homogeneous dose distribution and the
slightly protracted scheme may decrease toxicity. We are reporting
an analysis of the predictors for early toxicity after an 8-fraction
regimen on alternative days delivered by helical tomotherapy in
low-intermediate-high-risk prostate cancer patients.
MATERIALS AND METHODS
PATIENTS
This is a single institution phase II trial study approved in 2012
by the Salamanca University Hospital Institutional Review Board.
The main purpose was to study early and late side effects of SBRT
hypofractionated radiotherapy for prostate cancer with helical
tomotherapy. It was designed to enroll 107 patients, assuming a
loss of 10%.
The selection of patients, treatment planning, and delivery were
described in a previous article (18). Briefly, patients selected to be
included in the study had histologically confirmed adenocarci-
noma of the prostate cT1-3a, Gleason score <8, and initial PSA
<20 ng/mL. Since May 2013 patients over 70 years old with Glea-
son score 8 and PSA<10 ng/mL or PSA 20–40 ng/mL and Gleason
score ≤7 were also selected. Exclusion criteria were clinical stage
cT3b-4, involved lymph nodes or distant metastases on imaging,
prior pelvic radiotherapy, International Prostate Symptom Score
System (IPSS)>20, or history of acute urinary retention. Patients
were regrouped by version 3.2012 NCCN guidelines (low risk: PSA
<10 and Gleason sum of 6 and clinical stage T1c–T2a, interme-
diate risk: PSA 10–20 or Gleason sum of 7 or clinical stage T2b-c,
high-risk: PSA >20 or Gleason sum 8–10 or clinical stage T3a).
SIMULATION AND TREATMENT PLANNING
An anti-flatulence diet and mild oral laxatives were taken 2 weeks
before simulation CT until the end of radiotherapy treatment.
Bladder was filled with 250 ml contrast material through a urinary
catheter at the time of the simulation CT. Intraprostatic fiducials
were not implanted. The clinical target volume (CTV) included
the prostate and the proximal seminal vesicles (at the point where
the seminal vesicles separate). A contour was drawn around the
prostate gland with margins of about 2–5 mm, depending on the
prostate cancer risk group (19, 20). CTV to PTV margins were
based on recommendations of two series with image guidance
with implanted fiducials (21, 22). CTV was expanded 6 mm in the
craniocaudal direction, 3 mm posteriorly, 4–5 mm laterally, and
anteriorly up to symphysis pubis (about 7–10 mm). The rectum
was contoured as a solid organ up to 1 cm above and below the
PTV-containing sections. The posterior half of the rectum was also
contoured on each CT slice (23). Not more than the 2% of the vol-
ume should receive ≥37 Gy. This auxiliary volume was created to
help make a sharp dose gradient on the anterior rectum. Figure 1
shows the dose distribution on a typical patient. The prescription
dose was 43.84 or 45.2 Gy to the PTV delivered in eight fractions on
alternative days, which corresponds to a tumor equivalent dose at
2 Gy/fraction (EQD2) of approximately 87.4 or 92.3 Gy for NCCN
low risk and intermediate-high risk, respectively, assuming a α/β
ratio of 1.5 Gy. Correspondent figures for late-responding normal
tissues (α/β of 3 Gy) are 74.3 and 78.2 Gy, respectively. Dose was
FIGURE 1 | Dose distribution on a typical patient. CTV (brown), PTV
(red), 95% isodose (light blue), 37 Gy isodose (pink), 28 Gy isodose (dark
blue), 103% isodose (yellow).
prescribed to 95% of PTV. All cases were contoured, reviewed, and
approved by a single physician (Victor A. Macias).
TREATMENT DELIVERY
Megavoltage CT images (MVCT) were acquired before each frac-
tion using the on-board scanner of the Tomotherapy unit and
were co-registered to the simulation CT using automatic fusion of
bony anatomy and soft tissue. The registration was further man-
ually adjusted to account for inter-fractional motion. We ensured
that the prostate was within the 95% isodose, minimizing at the
same time the volume of rectum irradiated. Endorectal balloons
were not used. Patients measured the volume they urinated just
after each treatment fraction in order to have feedback informa-
tion to help keep their bladder volume between 200 and 300 cm3.
The median of the eight measurements was also recorded (MVU).
During radiotherapy, the patients were prescribed with 0.4 mg
tamsulosin and corticosteroid enema (fluocinilone).
HORMONAL THERAPY
Intermediate-high-risk patients were prescribed with an androgen
deprivation therapy (AD) before being sent to Radiation Oncol-
ogy, which consisted of one injection of 6-month gonadotropin-
releasing hormone agonist plus 50 mg/day bicalutamide for the
first month. AD was, therefore, neoadjuvant and concomitant to
radiation therapy.
FOLLOW-UP
Acute toxicity collects complications during radiotherapy and
the following 2 weeks. Toxicity was prospectively documented at
follow-up visits at month 1, 6, 12, 18, and 24 after the completion of
SBRT using the common terminology criteria for adverse events
(CTCAE) version 4.0. PSA and total testosterone were obtained
during the visits. IPSS questionnaires were filled out by patients
before radiotherapy, at the last fraction and during the follow-up
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visits. IPSS question eight (Q8) refers to the patient’s perceived
urinary-related quality of life. Biochemical failure was defined as
a rise of 2 ng/mL over nadir.
STATISTICAL ANALYSIS
All statistical analyses were performed with IBM SPSS software
version 21.0 and some graphics were made with Microsoft Excel
version 14.3.9 for Mac. The following variables were studied
as potential prognostic factors of acute toxicity: age, Charlson
Comorbidity Index, risk group, AD, total dose, basal IPSS, CTV,
PTV, rectal volume, bladder volume, and the median of the volume
of urine measured immediately after each of the eight fractions
(MVU) and finally, the amount of rectum or bladder (absolute
or percentage volume), which receives the dose levels used in the
treatment planning (≥43, ≥40, ≥37, ≥34, and ≥28 Gy). These
variables were also correlated with urinary or rectal toxicity dur-
ing follow up. Sample medians and ranges were used to describe
continuous variables, except age, whose mean and SD was used
instead. For qualitative variables, frequencies, and/or percentages
were used. It was examined whether the variables were correlated
with urinary or rectal toxicity along the follow-up. Student’s t -
test or ANOVA test were used with age, while U-Mann Whitney,
or Kruskal–Wallis tests were used with the other quantitative vari-
ables. Receiver operating characteristic curve (ROC curve) analysis
provided us the statistical methods to determine the cut-off value
for a variable with the highest sensitivity and specificity in order
to classify patients without toxicity versus with toxicity. The chi-
square test was used with qualitative variables. Student’ s t -test
and Wilcoxon test were used to assess differences in ongoing PSA
and quality of life scores (total IPSS score and Q8) in comparison
to the baseline. As reported by Chen et al. (24), the minimally
important difference (MID) in IPSS score was defined as a change
of one-half SD from the baseline.
RESULTS
DESCRIPTION OF OUR SERIES
In the period starting on May 2012 up to April 2014, 45 prostate
cancer patients were treated following the SBRT protocol at the
Salamanca University Hospital. Table 1 shows patient character-
istics. By NCCN classification, 71% belonged to the intermediate
or high-risk group. Eight of these were elderly men with Gleason
score 8 and PSA <10 ng/mL or PSA 20–40 ng/mL and Gleason
score≤7. Most patients (80%) had a Charlson Comorbidity Index
of 0–1. Thirty-two patients received 45.2 Gy at 5.65 Gy/fraction
and 13 patients received 43.84 Gy at 5.48 Gy/fraction. Plans were
homogeneous by design, with doses ranking from 95 to 103%
within the PTV. The 98% isodose covered at least 95% of the PTV
(median 99.2% of the PTV). A summary of the dose-volume his-
togram is shown in Table 2. The median volume of MVU is 260 ml
(range 125–400), suggesting bladder volume through the course
of radiotherapy is not very different from the bladder volume
contoured on the simulation CT.
The median follow-up is 13.8 months (range 2–25 months). All
patients but one were able to complete the treatment. That patient
died in an accident after the sixth fraction. Thirty-five patients
received neoadjuvant-concomitant AD for 6–26 months (median
6 months). The eight elderly high-risk selected patients above
Table 1 | Patient, tumor, and treatment characteristics.
Age Mean±SD (years) 70.40±7.19
Charlson comorbidity index 0 26/45(57.8%)
1 10/45 (22.2%)
2 8/45 (17.8%)
4 1/45 (2.2%)
IPSS pre-RT Median (range) 5 (0–14)
0–4 17/45 (37.8%)
5–9 16/45 (35.6%)
10–14 11/45 (24.4%)
NA 1/45 (2.2%)
PSA Median (ng/mL) 9
<10 25/45 (55.6%)
10–20 17/45 (37.6%)
>20 3/45 (6.7%)
cT stage 1c 19/45 (42.2%)
2a 4/45 (8.9%)
2b 6/45 (13.3%)
2c 2/45 (6.7%)
3a 13/45 (28.9%)
Pelvic MRI Yes 16/45 (35.6%)
No 29/45 (64.4%)
Gleason score 5 1/45 (2.2%)
6 22/45 (48.9%)
7 17/45 (37.8%)
8 5/45 (11.1%)
NCCN risk group Low 13/45 (28.9%)
Intermediate 17/45 (37.8%)
High 15/45 (33.3%)
Androgen deprivation (AD) Yes 35/45 (77.8%)
No 10/45 (22.2%)
Total dose (Gy) Median 45.2
Dose/fraction (Gy) Median 5.65
Irradiation time (s) Median (range) 513 (384–695)
AD duration (months) Median (range) 6 (6–26)
mentioned, also received neoadjuvant-concomitant AD, instead of
the neoadjuvant-concomitant-adjuvant AD for 2–3 years, which
is the standard for high-risk patients in our institution. Six out
of 13 low-risk patients were prescribed AD before being sent to
Radiation Oncology.
BIOCHEMICAL FAILURE
So far, there is one intermediate-risk patient that met the bio-
chemical failure definition at 17 months post-treatment. PSA rose
to 3.34 ng/mL after a nadir level of 0.44 ng/mL, however, it fell
to 2.09 ng/mL 2 months later. The upcoming PSA tests will serve
to distinguish true biochemical recurrence from a PSA bounce.
For the whole series, pre-treatment total PSA levels ranged from
1.2 to 34 ng/mL with a median value of 9 ng/mL. At 1 month
after SBRT, the median PSA value was 0.1 ng/mL (0.010–9.800)
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with a median total serum testosterone level of 19 ng/dL, while
at 12 months after radiotherapy the correspondent figures were
0.16 ng/mL (0.002–3.000) and 200 ng/dL.
TOXICITY
No grade 3 or 4 toxicities were encountered. Maximum urinary
and rectal complications are reported in Table 3. The acute uri-
nary toxicities were dysuria (18 grade 1 and 5 grade 2), nocturia
(13 grade 1 and 3 grade 2), urinary frequency (9 grade 1 and 3
grade 2), retention (4 grade 1 and 2 grade 2, one of which had
acute retention), and finally urgency (3 grade 1 and 2 grade 2).
The acute intestinal complications were proctitis/hemorrhoidal
pain during bowel movements (8 grade 1, 2 grade 2), frequency
with normal stool consistency (7 grade 1, 1 grade 2), bleeding (7
grade 1, 2 grade 2), tenesmus (3 grade 1, 4 grade 2), incontinence
(4 grade 1, 1 grade 2), abdominal pain (5 grade 1), and diarrhea
(2 grade 1 and 1 grade 2).
PREDICTORS OF TOXICITY
Regarding the small number of grade 2 toxicity events, we grouped
the patients into without (grade 0) or with toxicity (grade 1 or 2).
Table 2 | Summary of dose-volume histogram data.
Median Min Max
CTV (cm3) 113.70 53.00 209.90
PTV (cm3) 201.0 61.20 339.70
Rectum (cm3) 43.60 24.70 89.00
Bladder (cm3) 224.00 19.50 346.60
Penile bulb (cm3) 6.70 3.60 13.00
PTV V98% (%) 99.15 95.00 100.00
PTV D2% (Gy) 46.40 44.20 47.30
Rectum V43Gy (cm3) 2.7 0.1 12.70
Rectum V40Gy (cm3) 5.25 1.20 71.40
Rectum V37Gy (cm3) 7.45 3.60 22.60
Rectum V34Gy (cm3) 9.6 4.9 28.3
Rectum V28Gy (cm3) 14.65 8.3 45
Bladder V43Gy (%) 15.5 8.00 26.70
Bladder V40 Gy (%) 20.20 10.30 36.90
Bladder V37Gy (%) 25.40 13.50 46.20
Any dose-volume variable expressed as a percentage was correlated
with toxicity; nevertheless, some of them were correlated when
expressed as absolute volume (cubic centimeter). The probability
of having acute intestinal toxicity was statistically associated to the
volume of rectum receiving ≥28 Gy (p= 0.029). In our sample,
beyond 15 cm3, the probability of having acute intestinal toxicity
is over 60% (test efficacy 0.7045). Fifteen of the 45 patients had
a rectal volume of >15 cm3 receiving that dose. In contrast, only
five patients did not meet the dose limit actually used in the treat-
ment planning (the percentage of rectal volume receiving ≥28 Gy
should be less than 40%). In our trial, the age was a predictor of GI
toxicity after a month of treatment (p= 0.0005). Under 72 years
old, the probability of having GI toxicity is below 12% (test efficacy
0.63). No correlation was found between urinary toxicity and the
other analyzed variables.
QUALITY OF LIFE
Seventy-three percentage of the patients had mild to moderate
lower urinary tract symptoms prior to SBRT with a mean ini-
tial IPSS of 6.25 (range, 0–14, SD 3.75) (Figure 2). That score
increased significantly at the time of the last fraction (p= 0.000)
and at 1-month follow-up (p= 0.021), returning to baseline at
6 months (p= 0.196). One month post-treatment, however, mean
IPSS was barely above the MID (MID level 8.125). Urinary-related
quality of life (Figure 3), derived from the Q8 score, worsened
not significantly during radiotherapy (p= 0.107) returning to
the baseline levels at 1 month after the treatment. At 12 months
follow-up patient’s perception of their urinary function improved
significantly (p= 0.006) compared with baseline.
DISCUSSION
Presently, a handful of prospective studies using SBRT for prostate
cancer have been published, which have shown successful out-
comes with low toxicity profiles (2–8, 13–17). In an attempt to
overcome the problem of the small number of patients included
in each study, a consortium was formed to pool the available
data of phase II prospective trials from eight institutions that
used Cyberknife (9). A total of 1100 patient were enrolled with
a median follow-up of 36 months. The 5-year biochemical relapse
free survival rate was 95, 84, and 81% for low-, intermediate-, and
high-risk patients, respectively, supporting that Cyberknife SBRT
Table 3 | Prevalence of urinary and intestinal toxicities at each follow-up.
Urinary toxicity Intestinal toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 0 Grade 1 Grade 2 Grade 3
Acute 11/44 23/44 10/44 0/44 17/44 18/44 9/44 0/44
25% 52.27% 22.72% 0% 38.63% 40.90% 20.45% 0%
At 1 month 32/43 1/43 1/43 0/43 36/43 7/43 1/43 0/43
74.41% 2.30% 2.30% 0% 83.72% 16.28% 2.30% 0%
At 6 months 23/28 5/28 0/28 0/28 22/28 5/28 1/28 0/28
82.14% 17.85% 0% 0% 78.57% 17.86% 3.57% 0%
At 12 months 16/20 4/20 0/20 0/20 13/20 6/20 1/20 0/20
80% 20% 0% 0% 65% 30% 5% 0%
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FIGURE 2 | Urinary quality of life (IPSS questions 1–7). The scores range
from 0 to 35 with higher values representing worsening urinary symptoms.
Numbers above each time point indicate the number of observations
contributing to the average. The thresholds for minimally important clinical
differences (MID) are marked with dashed lines.
FIGURE 3 | Urinary quality of life (IPSS question 8). The score range
from 0 to 6 with higher values representing the patient is more dissatisfied
with his current urinary function.
can be considered as an appropriate therapeutic option for selected
patients. However, there is a limited experience on prostatic SBRT
delivered by conventional linear accelerator or helical tomother-
apy. Emerging data from single institutional series suggest that this
approach can achieve similar low rates of grade ≥3 early toxicity
compared with robotic SBRT (Table 4). Conventional LINACs
protocols usually use a more protracted overall treatment time
(alternate days or weekly fractions), reflecting the concern about
acute tolerance and consequential late effects. In a series of 64
patients who received five fractions of 7.25 Gy, every-other-day
treatments resulted in substantially less frequent grade 1–2 uri-
nary toxicity (17 vs. 56%, p= 0.007) and less frequent grade 1–2
rectal toxicity (5 vs. 44%, p= 0.001) compared with daily treat-
ments (10). Our study was designed to administer the treatment
fractions every-other-day over 2.5 weeks, while delivering to the
late-responding normal tissues the same biologically equivalent
dose as the standard 20-fraction hypofractionated scheme used in
our institution. In order to obtain a homogeneous dose distribu-
tion, avoiding hot spots over 105% in the periurethral zone of the
prostate, the full dose was prescribed to 95% of PTV, instead of
70–80% isodose usually used in HDR-like SBRT. With the aim of
reducing urinary symptoms, the Georgetown University Hospital
changed his Cyberknife SBRT protocol to limit the prescription
isodose from ≥70 to ≥80% and the maximum prostatic urethral
dose from 133 to 110%. In their opinion, the relatively high inci-
dence of acute urinary grade 3 observed in their series was caused
by the highly heterogeneous dose distribution inside the prostate,
with hot spots up to 40% above the prescribed dose, and also
by the patient selection, as they treated the patients not suitable
for brachytherapy (large volume, bad flow, high IPSS, TURP, or
abdominal surgery, hip joint prostheses) (2).
Inter-fraction changes in prostate shape are not uniform
throughout the length of the gland. A distended rectum can lead to
an anteroposterior shift in the cranial aspect of the gland and not in
the apex. As a result, it is sometimes the case that a correction com-
promises the adequate coverage of the anterior part of the CTV.
To avoid this, the PTV has been expanded anteriorly to the pubic
bone. This, together with the overestimation of prostate gland
volumes using traditional CT-based planning, since MRI was only
used for prostate cancer staging, results in larger CTV/PTV in our
series compared with Cyberknife studies.
A limitation of the study is the lack of assessment and manage-
ment of intrafraction motion. The deviation of prostate intrafrac-
tion motion distribution is a function of stool/gas volume. While
the effectiveness of dietary intervention, oral laxatives and rectal
enema is controversial (25–29), intrafraction motion is signifi-
cantly reduced by endorectal balloons (30), specially with longer
treatment times. An adequate patient preparation protocol before
treatment and the daily use of endorectal balloon can effectively
stabilized prostate motion for 90% of the fractions using a 3-
mm internal margin (31). Additionally, patients treated with a
water-filled endorectal balloon reported significantly less urgency
and incontinence, while their treatment plans showed significantly
lower doses to the anal wall, rectal wall and all pelvic floor muscles
(32). In our institution the inter-fraction prostate displacement is
taken into account by MVCT images with soft tissue registration
without fiducials. With manual registration of planning CT and
kV cone-beam CT (CBCT) without implanted markers the inter-
observer variability results in errors of 2–3 mm (33). CBCT with
implanted markers can decrease inter-observer variability within
2 mm compared with soft tissue alignment (34). So, considera-
tion needs to be given to margin design at each institution when
using soft tissue matching due to the above described increased
inter-observer variability.
We observed that the urinary function, measured on the
AUA/IPSS scale, recovered as in other non-robotic (16) and
Cyberknife trials (35–37). The median AUA score increased slightly
at the 1-month follow-up and then returned to baseline values at
3-month and subsequent follow-up intervals. Madsen et al. (16)
also found that after 12 months of follow-up, more than a half
of the patients reported improvement of their scores compared
to baseline. King et al. reported quality of life prospectively mea-
sured among 864 patients from phase II clinical trials of SBRT
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Table 4 | Acute toxicity SBRT in Cyberknife and non-robotic series.
GU grade 2 (%) GU grade 3 (%) GI grade 2 (%) GI grade 3 (%) Scheme
CYBERKNIFE
Aluwini et al. (2) 15 8 12 2 38 Gy/4 consecutive fx (SIB 44 Gy/4 fx in DIL)
Bolzicco et al. (3) 12 0 18 0 35 Gy/5 consecutive fx
Friedland et al. (4) – 0.9 – 0.9 35–36 Gy/5 consecutive fx
Kang et al. (5) 13.6 0 9.1 0 32–36 Gy/4 consecutive fx
Katz et al. (6) 4–4.7 0 3.6–4 0 35–36.25 Gy/5 consecutive fx
Oliai et al. (7) 19 4 4 0 36.25–37.5 Gy/5 consecutive fx
NON-ROBOTIC SBRTa
Alongi et al. (13) 40 0 10 0 35 Gy/5 fx on alternate days
Boike et al. (14) 7–33 0 0–27 0 45–50 Gy/5 fx separated ≥36 h
Loblaw et al. (15) 19 1 10 0 35 Gy/5 fx once a week
Madsen et al. (16) 21 2 13 0 33.5 Gy/5 consecutive fx
Menkarios et al. (17) 31 5 14 0 45 Gy/9 fx once a week
Current study 22.7 0 20.4 0 43.84–45.20 Gy/8 fx on alternate days
aRadiotherapy technique: volumetric modulated arc therapy (13), step and shoot IMRT (14–16), 3DCRT (17), helical tomotherapy (current study).
SIB, simultaneous integrated boost; DIL, dominant intraprostatic lesion.
(11). For urinary QOL, a significant but modest decline was also
most notable within the first 3 months, which had mostly recov-
ered by 6 months, remained stable thereafter. For those patients
with poorer urinary function at baseline (i.e., worst 25th or fifth
percentile), a gradual improvement in urinary QOL was in fact
observed beginning 6 months after treatment and progressing to
better than baseline function over the 6-years follow-up. No dif-
ferences were seen with the addition of AD or as a function of
patient age. A similar trend was seen for bowel QOL.
Low evidence is available on the predictors for acute toxic-
ity after prostate SBRT. We observed that the volume of rectum
receiving ≥28 Gy is correlated with acute intestinal toxicity. Kim
et al. enrolled 91 patients on a dose-escalation (from 45 to 50 Gy in
five fractions) phase I/II study (38). According to our results, they
observed that grade ≥2 acute rectal toxicity was significantly cor-
related with more than 50% of the rectal wall receiving≥24 Gy. In
their opinion, minimal vascular/stromal injury is likely to occur at
that dose level, allowing an adequate blood supply to the recruited
stem cells leading to an effective repair of the injury, provided that
less than half the rectal wall receives ≥24 Gy. We have observed
that the volume of rectum receiving a particular radiation dose
was an independent predictor of rectal toxicity when using actual
volume rather than percent volume. Others authors have had the
same findings and are then currently using actual rectal volume
when setting up planning constraints (39).
In our series, 71% of the patients are intermediate-high risk.
Most SBRT trials have only included low-risk cases due to the
concern that the tight margins required to limit the normal tissue
doses may not be adequate to treat the microscopic disease. Ju et al.
(37) reported that for the majority of their patients, treated with
Cyberknife SBRT, the coverage of the 33-Gy isodose line (76 Gy
EQD2, α/β 1.5) is more than 5 mm beyond the prostate, exclud-
ing posterior direction, where it is ≤3 mm in most cases. In our
study, one half of the seminal vesicles were included within the
CTV, and the PTV extended at least 5 mm from prostate gland.
In any patient, more than 95% of the PTV received the 98%
of the prescribed dose (equivalent to 92 Gy EQD2, α/β 1.5). We
therefore believe that our approach should effectively eradicate
the microscopic extraprostatic disease in high-risk prostate cancer
patients.
CONCLUSION
Our scheme of eight fractions on alternate days (EQD2= 87–
92 Gy, α/β 1.5) delivered using helical tomotherapy is well tol-
erated. We observe an impact on urinary quality of life at the end
of the radiotherapy treatment and 1 month later, with subsequent
recovery to baseline at 3 months follow-up. In order to decrease
acute toxicity, we recommend 15 cm3 as the cut-off of the rectal
volume not to exceed 28 Gy (EQD2= 48.4 Gy, α/β 3). However,
the rectal volume receiving that dose, expressed as a percentage,
was not correlated with the intestinal toxicity. That supports using
actual volume rather than percent volume in the treatment plan-
ning. The use of endorectal balloon catheters would help us to
reduce intrafraction movement, reduce moderate doses in lateral
and posterior rectal walls and to determine the position of the
anterior rectal wall at daily MVCT. A comparison between this 8-
fraction series and our contemporary 20-fraction series, with total
doses equivalent for late-responding tissues, is ongoing.
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